BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 10523468)

  • 1. The use of insulin alone and in combination with oral agents in type 2 diabetes.
    Buse JB
    Prim Care; 1999 Dec; 26(4):931-50. PubMed ID: 10523468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
    Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
    Bressler R; Johnson DG
    Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of insulin secretagogues in the treatment of type 2 diabetes.
    Luna B; Hughes AT; Feinglos MN
    Prim Care; 1999 Dec; 26(4):895-915. PubMed ID: 10523467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
    Hershon KS; Hershon PM
    Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes.
    Garber AJ
    Diabetes Obes Metab; 2000 Jun; 2(3):139-47. PubMed ID: 11220549
    [No Abstract]   [Full Text] [Related]  

  • 7. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
    Ohmura E; Hosaka D; Imai Y; Kawazu S
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacologic therapy for type 2 diabetes mellitus.
    DeFronzo RA
    Ann Intern Med; 1999 Aug; 131(4):281-303. PubMed ID: 10454950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.
    Caro JJ; Klittich WS; Raggio G; Kavanagh PL; O'Brien JA; Shomphe LA; Flegel KM; Copley-Merriman C; Sigler C
    Clin Ther; 2000 Jan; 22(1):116-27. PubMed ID: 10688395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination therapy with biguanides].
    Sakura H
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():724-8. PubMed ID: 12430309
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
    Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
    Bloomgarden ZT
    Diabetes Care; 1998 Jun; 21(6):1024-6. PubMed ID: 9614626
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
    Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
    Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
    [No Abstract]   [Full Text] [Related]  

  • 14. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
    Scheen AJ; Lefèbvre PJ
    Diabetes Care; 1999 Sep; 22(9):1568-77. PubMed ID: 10480527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
    Blonde L; Sandberg MI; Guthrie RD
    Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeted glycemic control in type 2 diabetes.
    Skyler JS
    J Fla Med Assoc; 1998 Aug; 85(2):7-15. PubMed ID: 9782713
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid.
    Evans JL; Heymann CJ; Goldfine ID; Gavin LA
    Endocr Pract; 2002; 8(1):29-35. PubMed ID: 11951812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
    Kitaoka H
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():464-9. PubMed ID: 12387035
    [No Abstract]   [Full Text] [Related]  

  • 19. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.
    Gavin LA; Barth J; Arnold D; Shaw R
    Endocr Pract; 2000; 6(4):305-10. PubMed ID: 11242607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Troglitazone].
    Yamanouchi T
    Nihon Rinsho; 2000 Feb; 58(2):389-94. PubMed ID: 10707563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.